Eckert & Ziegler Sees 25% Increase in Adjusted EBIT in Q3 2026

Eckert & Ziegler reported a 25% rise in adjusted EBIT for the third quarter of 2026, reaching €19.3 million compared to €15.4 million last year. The company's sales for this period increased to €79.6 million from €75.3 million, while net income rose to €13.1 million from €8.5 million. For the first nine months of 2026, sales climbed to €229 million, a 2% increase. The company's adjusted EBIT over this period was up 4%, and net income increased 19% to €35.4 million.

In the Medical segment, external sales for the first nine months totaled €121.4 million, driven by growth in pharmaceutical radioisotopes and the Contract Development & Manufacturing business. The Isotope Products segment saw a 3% rise in external sales. The company remains optimistic about achieving its 2026 forecast of €320 million in sales and €80 million in adjusted EBIT, supported by expected license revenues and radiopharmaceutical product demand.